Psychedelics and Depression: What the Research Shows

Persistent low mood and loss of interest that affects daily life. Research summaries and safety screening; Gabriel doesn't give psychedelic dosing.

Overview

Depression is the most studied use of psychedelic medicine. Researchers think psychedelics may help by loosening rigid patterns of thinking and supporting the brain's ability to form new connections, with effects that can outlast the session itself.

In trials, treatment includes careful screening, preparation sessions, a supervised session and follow-up support. Esketamine (Spravato) is the only drug in this group that is FDA-approved for depression as of October 2026.

Substances Being Studied

Ketamine

Strong

Ketamine is a dissociative anesthetic that blocks NMDA receptors in the brain, which affects glutamate signaling and may help rebuild connections between nerve cells weakened by chronic stress and depression. Unlike classic psychedelics, it does not work mainly through serotonin receptors, and it can act within hours rather than weeks. Esketamine (Spravato), a nasal spray made from one form of ketamine, was FDA-approved in 2019 for treatment-resistant depression alongside an oral antidepressant, and in January 2025 as a treatment on its own; in the monotherapy trial, 22.5% of people on esketamine reached remission at four weeks versus 7.6% on placebo. Esketamine is given only in certified clinics, with monitoring after each dose. Racemic ketamine is not FDA-approved for any psychiatric condition; clinics that give IV ketamine for depression use it off-label. In October 2023, FDA warned about compounded ketamine for psychiatric use, including oral forms prescribed by telehealth for use at home, because no one monitors patients during treatment. During a supervised treatment, ketamine causes dissociation, altered time perception and dreamlike states that usually fade within an hour or two.

Learn more →

Psilocybin

Strong

Psilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms. In the body it converts to psilocin, which activates serotonin 5-HT2A receptors in the brain, changing perception, mood and thinking for several hours. In clinical trials, psilocybin given with psychological support has reduced depression symptoms within days, with effects lasting weeks to months for some participants. Compass Pathways has run two Phase 3 trials of COMP360, a synthetic psilocybin, for treatment-resistant depression: in COMP005 (results June 2025) it beat placebo by 3.6 points on the MADRS depression scale at week 6, and in COMP006 (results February 2026) it beat a very low comparison dose by 3.8 points. As of October 2026, psilocybin is not FDA-approved; Compass says it is completing its application to FDA. Researchers at Johns Hopkins, NYU Langone, Imperial College London and other centers have also studied psilocybin for anxiety and depression in people with cancer, alcohol and tobacco use disorders, and obsessive-compulsive disorder. Trials pair it with preparation and follow-up sessions with trained therapists, and screen people carefully before treatment.

Learn more →

Ayahuasca

Moderate

Ayahuasca is a traditional Amazonian brew, usually made from the Banisteriopsis caapi vine and Psychotria viridis leaves. The vine contains harmala alkaloids that act as MAO inhibitors (MAOIs), which let the DMT in the leaves become active when swallowed, producing a visionary experience that usually lasts 4 to 6 hours. Indigenous peoples of the Amazon have used ayahuasca for generations in ceremonies for healing, spiritual guidance and community ritual. A small randomized trial in Brazil (2019) found that a single dose reduced depression scores in people with treatment-resistant depression compared with placebo, and observational studies have looked at ayahuasca for substance use disorders. Because the brew contains MAOIs, it can interact dangerously with antidepressants and many other medicines and substances. The experience usually involves vomiting and diarrhea, which traditional practitioners consider part of the ceremony.

Learn more →

LSD

Moderate

LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first made by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors and changes perception, mood and thinking for 8 to 12 hours. In the 1950s and 60s it was studied for alcoholism and anxiety before research stopped under prohibition. Modern trials have returned: Definium Therapeutics (formerly MindMed) reported positive Phase 3 results for its LSD drug candidate, DT120, in major depression (Emerge, June 2026) and generalized anxiety disorder (Voyage, August 2026), where it reduced symptoms more than placebo. As of October 2026, LSD is not FDA-approved; the company has said it plans to apply in 2027. A 2025 phase 2a trial of repeated low doses of LSD for adult ADHD did not beat placebo on its primary outcome. Earlier work at the University of Basel studied LSD-assisted therapy for anxiety in people with life-threatening illness, and neuroimaging studies at Imperial College London showed how LSD changes communication between brain networks.

Learn more →

DMT / 5-MeO-DMT

Emerging

DMT (N,N-dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, with intense but short effects. N,N-DMT is found in many plants and is the active compound in ayahuasca; inhaled, its effects last about 15 to 30 minutes and often include vivid visual patterns and a strong sense of meeting other beings. 5-MeO-DMT, found in some plants and in the venom of the Sonoran Desert toad (Incilius alvarius), tends to produce a loss of the sense of self rather than visual imagery. In a small phase 2a trial led at Imperial College London and published in Nature Medicine in February 2026, a single IV dose of DMT (SPL026) given with psychological support reduced depression scores more than placebo at two weeks. In a 2025 Phase 2b trial in 193 people with treatment-resistant depression, Beckley Psytech's intranasal 5-MeO-DMT (BPL-003) reduced depression scores more than a very low comparison dose, with no serious adverse events; a Phase 3 program was planned for 2026. Neither is FDA-approved. The trials use synthetic compounds. Toad-derived 5-MeO-DMT has no verified history of traditional indigenous use (modern toad ceremonies date from about 2015), and collecting the venom harms wild toad populations.

Learn more →

Ibogaine

Emerging

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central West Africa. The Bwiti tradition of Gabon has used iboga in spiritual initiation ceremonies for centuries. Ibogaine is studied mainly for opioid and other substance use disorders; observational studies report that a single treatment can reduce opioid withdrawal symptoms and cravings, but there are no completed randomized controlled trials. Researchers think it acts on several neurotransmitter systems, including dopamine, serotonin and opioid receptors. A typical ibogaine experience lasts 8-12 hours and involves a waking dream state with intense introspection, life review, and often vivid visions addressing the psychological origins of addiction. A 2024 Stanford study of 30 special operations veterans with traumatic brain injury (Nature Medicine), with no control group, reported large drops in PTSD, depression and anxiety symptoms one month after ibogaine given with magnesium. Ibogaine carries serious cardiac risks, including QT interval prolongation and fatal arrhythmias, and deaths have been reported. In 2025 Texas set aside $50 million for ibogaine clinical trials. As of October 2026, ibogaine is not FDA-approved for any use.

Learn more →

Peyote / Mescaline

Traditional

Peyote (Lophophora williamsii) is a small, spineless cactus containing mescaline as its primary psychoactive alkaloid. Sacred to the Native American Church (NAC), which has over 400,000 members across 50+ tribes, peyote serves as a holy sacrament in all-night ceremonies for spiritual communion, healing, and addressing personal and social imbalances. The NAC originated around 1885 among Kiowa and Comanche tribes, blending indigenous spirituality with Christian elements to preserve peyote traditions during persecution. Ceremonies occur in tipis around a crescent-shaped altar and sacred fire, running from Saturday evening through Sunday morning. Participants consume peyote (never smoked, only eaten dry, ground, or as tea) with prayer, singing, and contemplation, seeking guidance, healing, and communion with God and spirits. The Peyote Spirit is considered a deity providing visions, promoting brotherly love, family care, steady work, and abstinence from alcohol. Peyote contains more than 50 alkaloids; anthropologists have described sobriety as a goal of many Native American Church members, but controlled clinical research is minimal. Peyote is also a slow-growing, threatened cactus, and Native American Church leaders have asked non-Native people not to seek it out. The experience typically lasts 10-12 hours with enhanced perception, emotional openness, and spiritual insight.

Learn more →

San Pedro / Huachuma

Traditional

San Pedro (Echinopsis pachanoi), known as Huachuma in indigenous traditions, is a mescaline-containing cactus native to the Andes mountains of Peru, Bolivia, Ecuador, and surrounding regions. With over 4,000 years of ceremonial use, it is one of the oldest entheogens in the Americas, predating psilocybin mushroom use. Archaeological evidence from Peru's Chavín culture (1500 BCE) shows stone carvings of shamans holding the cactus. The Inca used San Pedro in ceremonies at Cusco, Machu Picchu, and the Sacred Valley for spiritual communion with deities, purification, divination, healing, and governance counsel. The primary psychoactive compound, mescaline, increases prefrontal cortex activity for emotional regulation and planning while producing heart-opening, empathogenic effects alongside visual enhancements. Traditional curanderos (healers) in Peru and Ecuador use San Pedro tea in blended indigenous-modern medicine for shamanic healing, enhancing perception, awakening intuition, and diagnosing mind-body-spirit imbalances. The experience, lasting 10-14 hours, typically brings euphoria, compassion, empathy, enhanced environmental awareness, and insights into personal problems. Modern clinical research on mescaline is very limited, so these traditional uses have not been tested in controlled trials.

Learn more →

What the Research Shows

Esketamine nasal spray is FDA-approved for treatment-resistant depression and for depression with suicidal thoughts, given in certified clinics. In two Phase 3 trials for treatment-resistant depression (2025 and 2026), Compass Pathways' synthetic psilocybin reduced depression scores more than the comparison; it is not FDA-approved. An LSD drug candidate (DT120) beat placebo in a Phase 3 trial for major depression in June 2026, and a small 2026 trial found a single dose of DMT reduced depression scores more than placebo at two weeks. These treatments were studied with psychological support, and none is a substitute for crisis care.

Safety Considerations

  • •Antidepressants such as SSRIs can interact with psychedelics. Never stop or change a prescribed medicine without your prescriber.
  • •Suicidal thoughts need prompt care from a clinician. If you are in crisis, call or text 988.
  • •Trials screen out people with a personal or family history of psychosis or bipolar disorder.
  • •Follow-up support after a session is part of every studied treatment.

Safety screening

Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:

  • Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
  • Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
  • MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
  • Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
  • A personal or family history of psychosis, schizophrenia or bipolar disorder.
  • Pregnancy or breastfeeding.

Never stop or change a prescribed medicine without your prescriber.

Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.

If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.

Questions? Ask Gabriel

Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.

Ask Gabriel

Explore Other Conditions

See what the research shows for other mental health, substance use and pain conditions.